search
Back to results

Transcranial Weak Current Stimulation Treatments for Working Memory Dysfunction in Schizophrenia

Primary Purpose

Schizophrenia, Schizo Affective Disorder

Status
Completed
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
transcranial direct current stimulation (tDCS)
Sponsored by
Oded Meiron
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizophrenia focused on measuring Working memory, Schizophrenia symtom severity,, Prefrontal tDCS, Event related EEG

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Ages 18-75
  • Primary diagnosis of DSM-IV schizophrenia (including schizoaffective disorder)
  • Right handed
  • Under stable doses of antipsychotic medication for ≥4 weeks
  • Normal vision by self report and physical exam
  • Use of effective method of birth control for women of childbearing capacity
  • Willing/capacity to provide informed consent
  • Outpatients or volunteering inpatients or involuntary patients with consent of legal guardian.

Exclusion Criteria:

  • Current or past history of substance dependence or abuse (excluding nicotine)
  • Other current Axis I disorders
  • History of seizure, epilepsy in self or first degree relatives, stoke, brain surgery, head injury, intracranial metal implants, known structural brain lesion, devices that may be affected by tDCS (pacemaker, medication pump, cochlear implant, implanted brain stimulator)
  • Frequent and persistent migraines
  • History of adverse reaction to neurostimulation
  • Participation in study of investigational medication within 6 weeks
  • Pregnancy
  • Women who are breast-feeding
  • Current significant laboratory abnormality

Sites / Locations

  • Herzog Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

active tDCS

Sham tDCS

Arm Description

active prefrotal tDCS: 20 mins pes tDCS session, twice a day for 5 days. Total of 10 ative tDCS sessions.

Sham prefrontal tDCS: sham stimulation 20 mins per session, twice a day for 5 days. Total of 10 sham stimulation sessions

Outcomes

Primary Outcome Measures

change in Positivie and Negative Syndrome Scale (PANSS, minimum score = 30, maximum score = 350, higher score indicate incresed ilness severity, lower scores indicate lower ilness severity) scores from baseline to post-tDCS intervention
change in total scores of the Positive and negative syndrome scale for Scizophrenia
change in working memory accuracy scores from baseline to post-tDCS intervention
change in verbal working memory accuracy (scores range from 0 to 126 correct responses)
change in working memory reaction times from baseline to post-tDCS intervention
change in mean reaction times of correct rsponses (i.e., hits) (measures in millisecods range from 400 to 2000 msec)

Secondary Outcome Measures

change in Mismatch neagtivity (MMN) event related potentials from baseline to post-tDCS intervention
change in MMN amplitudes from baseline to post-tDCS intervention (change in microVolts: change of 1 to 5 microvolts undet Fz electrode
change from baseline to post-tDCS intervention in Induced EEG theta power folowing verbal command
change in mean theta power activity (e.g., under Fz electrode, absolute power scale: µV2), change in mean absolute power of theta oscillations
change from baseline to post-tDCS intervention in Induced EEG alpha power folowing verbal command
change in mean alpha power activity (e.g., under Fz electrode, absolute power scale: µV2), change in mean absolute power of alpha oscillations

Full Information

First Posted
November 11, 2020
Last Updated
September 21, 2023
Sponsor
Oded Meiron
search

1. Study Identification

Unique Protocol Identification Number
NCT04637724
Brief Title
Transcranial Weak Current Stimulation Treatments for Working Memory Dysfunction in Schizophrenia
Official Title
Transcranial Weak Current Stimulation Treatments for Working Memory Dysfunction in Schizophrenia
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
November 29, 2019 (Actual)
Primary Completion Date
August 30, 2023 (Actual)
Study Completion Date
September 10, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Oded Meiron

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
For the present study, Investigators will examine the efficacy of active prefrontal anodal tDCS versus placebo (sham) interventions to treat WM dysfunction in schizophrenia. Investigators selected the prefrontal stimulation modality that proved most effective in enhancing high-load WM performance in single dose stimulation in healthy participants . The study employs a multi-stimulation approach, with 2 sessions per day for 5 consecutive days in the active treatment group (n=15) compared to a group that receives only sham stimulation (n=15). This preliminary approach is based upon findings of a recent study applying cathodal tDCS stimulation over left temporoparietal cortex (with left prefrontal anodal stimulation) for the treatment of persistent auditory hallucinations in schizophrenia. In a a recent study clinical benefits were maintained for at least 3 months following stimulation. In the present study, in addition to clinical outcome, researchers will evaluate whether similar improvement can be obtained with WM, EEG activity, and functional outcome (e.g., discharged from hospitalization following significant improvement or remission).
Detailed Description
In a recent tDCS study investigators conducted with 41 healthy participants, researchers administered a single blind tDCS protocol that included an active unilateral DLPFC condition (2 mA for 15 minutes, anode over the left DLPFC (midpoint between F3-AF3) and cathode over the dorsal area of the superior parietal cortex (at Cz) versus a sham condition to investigate changes in online working memory function. Our preliminary tDCS results indicated gender-dependent (left enhancement in males versus females) high-load WM enhancement during active prefrontal stimulation versus sham stimulation. The observed prefrontal tDCS enhancing effect on high-load WM function indicated that left DLPFC tDCS could be implemented with SZP who suffer from inefficient left DLPFC engagement during medium to high-load WM maintenance. Given the lack of effective treatments for attenuating WM impairments and the importance of these impairments to functional outcome in schizophrenia, tDCS based cognitive-enhancing approaches may become an important new treatment method, which will consequently improve treatment and functional outcome in schizophrenia patients.The innovative nature of the study's proposed research project is that it promotes non-invasive focal (left prefrontal cortex) neuromodulation to improve cognitive functioning as well as illness severity in SZP. Most importantly, unlike antipsychotic medication that affects the entire brain circuitry and produces undesired side effects (e.g., extrapyramidal effects, weight gain, hyperlipidemia, and sexual dysfunction), the current non-invasive focal intervention is aimed at reducing specific prefrontal dysfunctions in schizophrenia by specific targeting of prefrontal electrophysiological disturbances (e.g., frontal theta synchrony) within regions known to regulate behavior and the consolidation of goal-directed information. Hypothesis Essentially, currently proposed tDCS treatment is hypothesized to improve working memory functioning and reduce symptom severity in people diagnosed with schizophrenia versus sham prefrontal tDCS (placebo).The theoretical premise for our prediction implies that effective inhibition of excessive dopaminergic mesolimbic activity (impaired in schizophrenia), could result from excitatory left-prefrontal tDCS, which has been shown to increase executive regulation of behavior in healthy individuals and people diagnosed with schizophrenia . Research plan outline For the present study, investigators will examine the efficacy of active prefrontal anodal tDCS versus placebo (sham) interventions to treat WM dysfunction in schizophrenia. Investigatros selected the prefrontal stimulation modality that proved most effective in enhancing high-load WM performance in single dose stimulation in healthy participants. A multi-stimulation approach is implemnted, with 2 sessions per day for 5 consecutive days in the active treatment group (n=15) compared to a group that receives only sham stimulation (n=15). This preliminary approach is based upon findings of a recent study applying cathodal tDCS stimulation over left temporoparietal cortex (with left prefrontal anodal stimulation) for the treatment of persistent auditory hallucinations in schizophrenia . In a recent study clinical benefits were maintained for at least 3 months following stimulation. In the present study, in addition to clinical outcome, we will evaluate whether similar improvement can be obtained with WM, EEG activity, and functional outcome (e.g., discharged from hospitalization following significant improvement or remission). In regards to efficacy, since WM is considered a core cognitive deficit in schizophrenia, investigators will monitor working memory, psychosis severity and global outcome, at baseline, immediately following tDCS intervention, and at 1, 4, and 8, 12, and 16 week intervals, following the termination the five-day treatment. Importantly, in order to show external validity of our efficacy analysis we will examine functional outcome (level of independence), six months after the termination of the tDCS intervention. Finally, since DLPFC stimulation may contribute to long-term electroencephalography (EEG) theta- rhythm functional connectivity, associated with increased large-scale theta synchronization, WM function, and episodic memory formation, investigatros will examine effects of tDCS on prefrontal versus whole-brain EEG theta activity obtained during a WM task (see verbal n-Back task), using event-related potential (ERP) and event-related spectral power (ERSP) techniques similar to those in used in recent EEG studies in schizphrenia patients. Demonstrating significant functional-connectivity EEG differences in responders versus non-responders from baseline to post-intervention measurements will significantly increase the validity of our proposed prefrontal pathophysiological mechanism as significantly impacting psychosis severity and clinical outcome in schizophrenia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia, Schizo Affective Disorder
Keywords
Working memory, Schizophrenia symtom severity,, Prefrontal tDCS, Event related EEG

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Active tDCS versus Sham tDCS intervention
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
33 (Actual)

8. Arms, Groups, and Interventions

Arm Title
active tDCS
Arm Type
Experimental
Arm Description
active prefrotal tDCS: 20 mins pes tDCS session, twice a day for 5 days. Total of 10 ative tDCS sessions.
Arm Title
Sham tDCS
Arm Type
Sham Comparator
Arm Description
Sham prefrontal tDCS: sham stimulation 20 mins per session, twice a day for 5 days. Total of 10 sham stimulation sessions
Intervention Type
Device
Intervention Name(s)
transcranial direct current stimulation (tDCS)
Other Intervention Name(s)
Prefrontal tDCS
Intervention Description
10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.
Primary Outcome Measure Information:
Title
change in Positivie and Negative Syndrome Scale (PANSS, minimum score = 30, maximum score = 350, higher score indicate incresed ilness severity, lower scores indicate lower ilness severity) scores from baseline to post-tDCS intervention
Description
change in total scores of the Positive and negative syndrome scale for Scizophrenia
Time Frame
Immediately after 10-day tDCS-intervention
Title
change in working memory accuracy scores from baseline to post-tDCS intervention
Description
change in verbal working memory accuracy (scores range from 0 to 126 correct responses)
Time Frame
Immediately after 10-day tDCS intervention
Title
change in working memory reaction times from baseline to post-tDCS intervention
Description
change in mean reaction times of correct rsponses (i.e., hits) (measures in millisecods range from 400 to 2000 msec)
Time Frame
Immediately after 10-day tDCS intervention
Secondary Outcome Measure Information:
Title
change in Mismatch neagtivity (MMN) event related potentials from baseline to post-tDCS intervention
Description
change in MMN amplitudes from baseline to post-tDCS intervention (change in microVolts: change of 1 to 5 microvolts undet Fz electrode
Time Frame
Imediatly after after 10-dat tDCS intervention
Title
change from baseline to post-tDCS intervention in Induced EEG theta power folowing verbal command
Description
change in mean theta power activity (e.g., under Fz electrode, absolute power scale: µV2), change in mean absolute power of theta oscillations
Time Frame
Immediatly after tDCS intervention
Title
change from baseline to post-tDCS intervention in Induced EEG alpha power folowing verbal command
Description
change in mean alpha power activity (e.g., under Fz electrode, absolute power scale: µV2), change in mean absolute power of alpha oscillations
Time Frame
Immediatly after tDCS intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ages 18-75 Primary diagnosis of DSM-IV schizophrenia (including schizoaffective disorder) Right handed Under stable doses of antipsychotic medication for ≥4 weeks Normal vision by self report and physical exam Use of effective method of birth control for women of childbearing capacity Willing/capacity to provide informed consent Outpatients or volunteering inpatients or involuntary patients with consent of legal guardian. Exclusion Criteria: Current or past history of substance dependence or abuse (excluding nicotine) Other current Axis I disorders History of seizure, epilepsy in self or first degree relatives, stoke, brain surgery, head injury, intracranial metal implants, known structural brain lesion, devices that may be affected by tDCS (pacemaker, medication pump, cochlear implant, implanted brain stimulator) Frequent and persistent migraines History of adverse reaction to neurostimulation Participation in study of investigational medication within 6 weeks Pregnancy Women who are breast-feeding Current significant laboratory abnormality
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alex Borochov, MD
Organizational Affiliation
Herzog Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Herzog Medical Center
City
Jerusalem
ZIP/Postal Code
91035
Country
Israel

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
non personal coded data indicating the participants change in working memory scores, change in psychosis severiry PANSS scores, and change in MMN amplitudes: comparing active tDCS group versus shham-tDCS group
Citations:
PubMed Identifier
22581236
Citation
Brunelin J, Mondino M, Gassab L, Haesebaert F, Gaha L, Suaud-Chagny MF, Saoud M, Mechri A, Poulet E. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry. 2012 Jul;169(7):719-24. doi: 10.1176/appi.ajp.2012.11071091. Erratum In: Am J Psychiatry. 2012 Dec 1;169(12):1321.
Results Reference
background
PubMed Identifier
33894334
Citation
Meiron O, David J, Yaniv A. Left prefrontal transcranial direct-current stimulation reduces symptom-severity and acutely enhances working memory in schizophrenia. Neurosci Lett. 2021 Jun 11;755:135912. doi: 10.1016/j.neulet.2021.135912. Epub 2021 Apr 21.
Results Reference
derived

Learn more about this trial

Transcranial Weak Current Stimulation Treatments for Working Memory Dysfunction in Schizophrenia

We'll reach out to this number within 24 hrs